Active Implantable Medical Devices Market is expected to reach US$ 22,096.9 Mn with a CAGR of 7.9% from 2018-2025
iCrowd Newswire
01 Jul 2021, 11:57 GMT+10
According to The Insight Partners market research study titled Active Implantable Medical Devices Market to 2025 – Global Analysis and Forecasts by Product and End User, the global active implantable medical devices market was valued at US$ 22,096.9 Mn in 2017 and is estimated to reach US$ 39,026.9 Mn by 2025. The market is estimated to grow with a CAGR of 7.9% from 2018-2025. The report highlights the trends prevalent in the global active implantable medical devices market and the factors driving the market along with those that act as deterrents to its growth.
Surgical Gloves Market is expected to reach US$ 5,028.07 million With CAGR of 10.3% from 2020 to 2027
iCrowd Newswire
01 Jul 2021, 11:57 GMT+10
According to our new market research study on Surgical Gloves Market to 2027 – Global Analysis and Forecast – by product, applications and end user, the market is expected to reach US$ 5,028.07 million by 2027 from US$ 2,292.03 million in 2019. The market is estimated to grow with a CAGR of 10.3% from 2020 to 2027. The report highlights trends prevailing in the market, and drivers and hindrances pertaining to the market growth.
Global Surgical Gloves market, based on Raw Material is segmented into latex gloves, nitrile gloves, vinyl gloves, neoprene gloves, polyisoprene gloves, and Biogel gloves. In 2019, the latex gloves segment accounted for the highest share of the market. Growth of this segment is attributed to the advantage of latex for making gloves is due to its elasticity. The Biogel gloves segment is likely to register high
Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
and Chair of the Steering Committee
for SOS-AMI, commented: P2Y
12 receptor antagonists have been used in the treatment of millions of patients globally, and their safety and efficacy profiles are well established. Despite the success of chronic treatment with this class and other effective interventions, patients are still suffering recurrent heart attacks. The idea for patients to self-inject early in the onset of symptoms is truly innovative. The subcutaneous route of administration could overcome the onset delay observed with oral compounds from the same class.
To be effective, any antithrombotic treatment for use at the onset of AMI symptoms should be rapidly absorbed and potent, acting quickly to inhibit thrombus formation at an early stage. Inhibition should be reversed after a few hours to avoid interfering with later patient management decisions. It must also have an appropriate safety profile for use prior to formal diagnosis of AMI. Selatogrel has the potential to s
Novocardia™ Announces $53 7 Million Financing Led by Deerfield Management prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.